FLT3 mutations in Early T-Cell Precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors by Neumann, Martin et al.
FLT3 Mutations in Early T-Cell Precursor ALL Characterize
a Stem Cell Like Leukemia and Imply the Clinical Use of
Tyrosine Kinase Inhibitors
Martin Neumann
1, Ebru Coskun
1, Lars Fransecky
1, Liliana H. Mochmann
1, Isabelle Bartram
1,
Nasrin Farhadi Sartangi
1, Sandra Heesch
1, Nicola Go ¨kbuget
2, Stefan Schwartz
1, Christian Brandts
2,
Cornelia Schlee
1, Rainer Haas
3, Ulrich Du ¨hrsen
4, Martin Griesshammer
5, Hartmut Do ¨hner
6,
Gerhard Ehninger
7, Thomas Burmeister
1, Olga Blau
1, Eckhard Thiel
1, Dieter Hoelzer
2,
Wolf-Karsten Hofmann
8, Claudia D. Baldus
1*
1Charite ´, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany, 2Goethe University Hospital, Department of
Medicine II, Hematology and Oncology, Frankfurt/Main, Germany, 3Department of Hematology and Oncology, University of Du ¨sseldorf, Du ¨sseldorf, Germany,
4Department of Hematology and Oncology, University of Essen, Essen, Germany, 5Department of Hematology and Oncology, Klinikum Minden, Minden, Germany,
6Department of Internal Medicine III, University of Ulm, Ulm, Germany, 7Department of Hematology and Oncology, University of Dresden, Dresden, Germany,
8University Hospital Mannheim, Department of Hematology and Oncology, Mannheim, Germany
Abstract
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) has been identified as high-risk subgroup of acute T-
lymphoblastic leukemia (T-ALL) with a high rate of FLT3-mutations in adults. To unravel the underlying pathomechanisms
and the clinical course we assessed molecular alterations and clinical characteristics in a large cohort of ETP-ALL (n=68) in
comparison to non-ETP T-ALL adult patients. Interestingly, we found a high rate of FLT3-mutations in ETP-ALL samples
(n=24, 35%). Furthermore, FLT3 mutated ETP-ALL was characterized by a specific immunophenotype (CD2+/CD5-/CD13+/
CD33-), a distinct gene expression pattern (aberrant expression of IGFBP7, WT1, GATA3) and mutational status (absence of
NOTCH1 mutations and a low frequency, 21%, of clonal TCR rearrangements). The observed low GATA3 expression and high
WT1 expression in combination with lack of NOTCH1 mutations and a low rate of TCR rearrangements point to a leukemic
transformation at the pluripotent prothymocyte stage in FLT3 mutated ETP-ALL. The clinical outcome in ETP-ALL patients
was poor, but encouraging in those patients with allogeneic stem cell transplantation (3-year OS: 74%). To further explore
the efficacy of targeted therapies, we demonstrate that T-ALL cell lines transfected with FLT3 expression constructs were
particularly sensitive to tyrosine kinase inhibitors. In conclusion, FLT3 mutated ETP-ALL defines a molecular distinct stem cell
like leukemic subtype. These data warrant clinical studies with the implementation of FLT3 inhibitors in addition to early
allogeneic stem cell transplantation for this high risk subgroup.
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Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
leukemia accounting for 10–15% of childhood and 25% of adult
ALL cases. Based on molecular studies, T-ALL can be divided into
at least four molecular-cytogenetic subgroups, i.e. the TAL/LMO,
the TLX/HOX11, the TLX3/HOX11L2 and the HOXA subgroups
[1–3]. Apart from these genetic subgroups, a fifth subgroup of T-
ALL cases with developmental arrest at a very early stage of T-cell
development was defined by a characteristic early T-cell precursor
(ETP) signature in pediatric T-ALL [4]. This T-ALL subtype,
termed as ETP-ALL, is described by an immature surface
immunophenotype: absence of CD1a and CD8 expression, weak
CD5 expression and expression of one or more myeloid-associated
and/or stem cell-associated markers. In addition, an increased
genomic instability, a high frequency of remission failures and
hematologic relapse characterize this highly unfavorable T-ALL
subgroup in pediatric patients [4].
Oncogenic alterations that lead to a differentiation arrest at
specific stages of T-cell development are well known for specific
subgroups of T-ALL. Of these, the overexpression of the orphan
homeobox proteins TLX1 and TLX3 lead to a maturation block
due to ETS1-mediated TLX recruitment to the Ea core [5]. Most
recently, for the group of ETP-ALL a mutational spectrum similar
to acute myeloid leukemia (AML) was observed, however no single
genetic alterations could be tracked down [6]. For the majority of
T-ALL, activation of NOTCH1 signalling is a driving force in the
pathogenesis [7]. Activating NOTCH1 mutations have been found
in more than 60% of T-lineage leukemias and result in a ligand-
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subsequently translocates to the nucleus, where it acts as
transcriptional co-activator [8–11]. Various groups have shown
that activated NOTCH1 signalling causes activation of downstream
targets including HES1, DTX1, PTCRA, and MYC and clinical
studies have explored gamma secretase inhibitors (GSI) as targeted
therapeutic strategy in T-ALL [12–14].
In contrast to the high frequency of NOTCH1 mutations,
activating FLT3 mutations (FLT3mut) occur only in a very low
frequency of T-ALL cases (1–3%), but were evaluated in only
limited patient series [15–17]. In contrast, mutations of the FLT3
gene, including internal tandem duplications (ITD) and tyrosine
kinase domain (TKD) mutations, are one of the most frequent
somatic alterations in AML. About one third of AML patients
harbor these alterations, which are associated with a poor
prognosis in both, adult and pediatric AML [18,19]. These
findings have promoted the use of tyrosine kinase inhibitors (TKI)
in patients with FLT3 mutated AML [20,21].
Recently, we have characterized ETP-ALL as a subgroup of
early T-ALL in adults [22]. To unravel the underlying
pathomechanisms of ETP-ALL and to extend our insights on
FLT3mut ETP-ALL, we performed a comprehensive molecular
and clinical study on a large cohort of adult ETP-ALL patients.
We were able to demonstrate that FLT3mut ETP-ALL could be
classified by its specific immunophenotype and distinctive stem cell
like characteristics. Moreover, T-lymphoblastic cells transfected
with FLT3-ITD constructs were particular sensitive to tyrosine
kinase inhibition making this a new and potentially useful
therapeutic option.
Materials and Methods
Patients and treatment
We screened 1241 peripheral blood and bone marrow samples
of T-ALL patients that were sent to the central diagnostic
reference laboratory of the German Acute Lymphoblastic
Leukemia Multicenter Study Group (GMALL). Most cases were
characterized with monoclonal antibodies to precursor cells
(CD10, CD34, CD117, TdT and HLA-DR) and with a selection
of lymphoid-associated antigens including surface and cytoplasmic
(c) antigens (cCD79a, CD22, cIgM, CD19, CD20, CD24, CD3,
TCR, CD2, CD5, CD4, CD8, CD7, CD1a) and myeloid-
associated antigens including myeloperoxidase (MPO), CD13,
CD33, CD65s, CD15, CD14, CD64. An antigen was considered
positive, if they were expressed in $20% of leukemic cells (10% for
cytoplasmic antigens). Classification of ETP-ALL was based on the
immunophenotypic diagnostic criteria as originally described [4]:
CD5 ,75%; CD1a and CD8 ,5%; CD117, CD34, HLA-DR,
CD13, CD33, and CD65s .25%. CD11b was not determined
(Suppl. Table S1). Of all immunophenotypically identified ETP-
ALL patients (n=142), sufficient material for further investigations
was available in 68 cases. Sixteen of these 68 patients were already
included in a previous work [22]. For 52 of these 68 patients
clinical follow-up data were available. The median follow-up was
9.4 months (range: 0–124.6 months). Most patients were treated
according to protocols of the GMALL study group (43/46, 93%
by medical report, Table 1). In addition, 94 T-ALL patients from
the GMALL trial 07/2003 were used as reference group, of which
nine patients showed an ETP-ALL immunophenotype and were
included in the cohort of 68 ETP-ALL patients [23,24]. Of the
remaining 85 non-ETP T-ALL patients, 17 had an immunophe-
notype of early T-ALL, 15 of mature T-ALL, and 53 of thymic T-
ALL. All patients gave written informed consent to participate in
the study according to the Declaration of Helsinki. The studies
were approved by the ethics board of the Johann Wolfgang
Goethe-Universita ¨t Frankfurt/Main, Germany.
Nucleic acid preparation and molecular characterization
Pretreatment bone marrow and peripheral blood samples from
patients were used for DNA and total RNA extraction using
TRIzol (Life Technologies, Grand Island, NY, USA) according to
the manufacturer’s protocol with minor modifications. Comple-
mentary DNA (cDNA) was synthesized using 500 ng of total RNA
and avian myeloblastosis virus reverse transcriptase (RT-AMV;
Roche, Mannheim, Germany) in the presence of RNase inhibitor
(RNasin; Roche, Mannheim, Germany).
The samples were investigated by comparative real-time PCR
(RT-PCR) for expression of eight genes (BAALC, ERG, IGFBP7,
WT1, MN1, GATA3, BCL11B, and MEF2C). The mRNA
expression levels for WT1 [25], BAALC [24], IGFBP7 [26], and
ERG [24] were determined by RT-PCR as previously described.
MN1-primers were designed as reported [27]. Primer sequences
for the expression analysis of GATA3, BCL11B and MEF2C are
available on request.
The NOTCH1 mutation status was defined by direct sequencing
of the N-terminal and the C-terminal region of the HD domain,
the N-terminal and the C-terminal region of the PEST domain,
and the TAD domain [28,29].
WT1 mutations were analysed as recently reported [25].
FLT3mut (ITD/TKD) were analyzed using a commercially
available FLT3 mutation assay (InVivoScribe Technologies, San
Diego, USA). The TCR rearrangement status was assessed by the
IdentiCloneTM TCRG Gene Clonality Assay (InVivoScribe
Technologies, San Diego, USA).
Statistical analysis
Differences in the clinical characteristics were tested by the
Pearson x
2 test. For overall survival (OS) in the different
subgroups, Kaplan-Meier curves were created and compared by
the Log-rank test. OS was calculated from the time-point of study
entry to the time-point of death or last follow-up (censored).
The statistical difference of gene expression between two
independent groups was tested by the nonparametric Mann-
Whitney-U-test. Differences in the mutation rates were analyzed
by the Pearson x
2 or the Fisher’s exact test. For all tests a P-
value,0.05 (two-sided) was considered to indicate a significant
difference. All calculations were performed using the SPSS
software version 19 (SPSS Inc., Chicago, IL, USA) and GraphPad
Table 1. Gene expression levels in ETP-ALL compared to non-
ETP T-ALL.
Expression
ETP-ALL
(N=68)
non-ETP T-ALL
(N=85) P-value
BAALC median (range) 0.69 (0.0–27.1) 0.08 (0.0–160.3) ,.001
IGFBP7 median (range) 1.24 (0.01–4.2) 0.49 (0.0–16.2) .009
WT1 median (range) 0.53 (0.0–4.2) ,0.01 (0.0–1.6) ,.001
ERG median (range) 1.16 (0.0–18.6) 10.69 (0.5–136.7) ,.001
MN1 median (range) 4.59 (0.0–33.1) 0.66 (0.01–2.7) ,.001
BCL11B median (range) 0.09 (0.0–1.4) 0.44 (0.0–9.9) ,.001
GATA3 median (range) 2.11 (0.0–27.3) 3.91 (0.3–32.4) .005
MEF2C median (range) 0.50 (0.0–5.1) 0.20 (0.0–1.7) .001
P values were calculated by Mann-Whitney-U-test.
doi:10.1371/journal.pone.0053190.t001
FLT3 Mutated ETP-ALL
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Cell culture and chemicals
The human mature T-cell leukemia cell lines Jurkat, BE13 and
MOLT-4 were obtained from the German Resource Center for
Biological Material, DSMZ (Braunschweig, Germany) and previ-
ously characterized on a molecular level [30]. They were grown in
RPMI media with 10% fetal bovine serum. All cell lines were
cultured at 37uC in a 5% CO2 humidified chamber. TKI258 was
a kind gift from Novartis (Basel, Switzerland). Tyrosine kinase
inhibitors Sorafenib and PKC412 were purchased from Alexis/
Enzo Life Sciences (BAY 43-9006; Loerrach, Germany) and LC
Laboratories (Woburn, MA, USA) respectively. The chemother-
apeutic agent cytarabine (AraC) was provided by Merck Chem-
icals (Darmstadt, Germany).
Plasmid constructs and transfection
For transduction of Jurkat, BE13 and MOLT-4, 2610
6 cells
were transfected with either FLT3-ITD, or FLT3-wt expression
constructs and with the empty vector as a control, using the
Nucleofector systems (Lonza Cologne AG, Cologne, Germany)
according to the manufacturer’s recommendations. The final
concentration of the constructs and the empty vector control was
2 mg. FLT3-wt and FLT3-ITD expression constructs were
previously described [31].
Cell proliferation assay
Cell proliferation was measured with the WST-1 reagent
according to the manufacturer’s instructions (Roche Diagnostics
GmbH, Germany). Briefly, 48 hours (hrs) after transfection with
FLT3 constructs and empty vector control, the cells were seeded in
a 96-well plate with 2610
5/well. Subsequently, the cells were
cultured for 48 hrs with Sorafenib, PKC412, TKI258 and AraC
as a chemotherapy agent or Dimethylsulfoxid (DMSO) as negative
control. Absorbance was measured after 48 hrs by optical density
absorption analyses at 450 nm using an ELISA multiplate reader.
The 50% growth inhibitory concentrations (IC50) of Sorafenib,
PKC412 and TKI258 were determined by plotting the logarithm
of the drug concentrations (Sorafenib: 0–500 mM, PKC412: 0–
18 nM, TKI258: 0–500 nM) and the growth rate of the cells
treated with FLT3-ITD or FLT3-wt constructs and empty vector,
using the WST-1 assay.
Apoptosis assay
The cellular apoptosis was measured transfected with FLT3-
ITD or FLT3-wt constructs and with the empty vector. Briefly,
after 48 hrs treatment with Sorafenib, PKC412, TKI258, and
AraC cells were labelled with Annexin V and 7-amino-actinomy-
cin D (7-AAD), using Annexin V Apoptosis Detection Kit (BD
Pharmingen, Heidelberg, Germany) and then analyzed by FACS
Calibur (Becton-Dickinson) to determine the percentage of
apoptotic cells.
Results
Characteristics and clinical outcome of adult ETP-ALL
patients
Based on the ETP-ALL specific immunophenotype, we
identified pre-treatment samples of 68 newly diagnosed ETP-
ALL patients. The median age was 38 years (range: 17–74 years).
More patients were male (81%). Of all 68 ETP-ALL patients,
follow-up data were available in 52 patients. Forty-five patients
were treated according to a GMALL-like protocol, three patients
to an AML-like protocol. Fifty-eight percent of patients achieved a
complete remission (CR) after induction therapy (Supplementary
Table S2). The cumulative 3-year OS was 60%. We further
examined outcome with respect to the treatment of chemotherapy
only or the allocation to allogenic stem cell transplantation
(alloSCT). With the limitation of a potential selection bias for
patients undergoing alloSCT, we observed for ETP-ALL patients
receiving an alloSCT a favorable outcome (n=20; 3-year OS:
74%) compared to ETP-ALL patients that were treated with
chemotherapy only (n=19; 3-year OS: 37%, P=0.006; Figure 1).
To address the potential selection bias we have also performed a
landmark analysis with a time to transplant of two months. In this
analyses patients undergoing alloSCT showed a favourable
however not significant benefit compared to patients only
receiving chemotherapy.
Aberrant gene expression and mutational analyses in
ETP-ALL compared to non-ETP T-ALL
To further characterize ETP-ALL on the molecular level, we
analyzed this large ETP-ALL cohort for the expression of selected
genes involved in the pathogenesis and with prognostic implica-
tions in adult acute leukemia [22]. BAALC and IGFBP7 were
higher expressed in ETP-ALL compared to non-ETP T-ALL
patients (BAALC, 8.6-fold, P,.001; IGFBP7, 2.5-fold, P=.009).
Furthermore, expression levels of WT1 and MN1 were higher in
ETP-ALL compared to non-ETP T-ALL (WT1,P ,.001; MN1,7 -
fold, P,.001). Additionally, expression of MEF2C, a gene
associated with ETP-ALL [32], was significantly higher in ETP-
ALL versus non-ETP T-ALL (2.6-fold, P=.001). As critical
players in the differentiation program of T-lymphopoiesis, we
explored the expression of the transcription factors GATA3,
required for the development of normal ETPs [33], and BCL11B,
necessary for the subsequent T-cell lineage commitment [34].
Both, GATA3 and BCL11B, were lower expressed in ETP-ALL
compared to non-ETP T-ALL (1.9-fold, P=.005; and 4.9-fold,
P,.001; respectively). Similarly, ETS transcription factor ERG
was also significantly downregulated in ETP-ALL vs. non-ETP T-
ALL (9.2-fold, P,.001; Table 1) [35].
The analysis of the TCR rearrangement status revealed that 40
ETP-ALL patients (59%) lacked clonal TCR rearrangements,
while 28 patients (41%) showed a monoclonal status. In contrast,
66 (78%) of non-ETP T-ALL patients showed clonal TCR
rearrangements, whereas only 18 of these patients (22%) lacked
monoclonal TCR rearrangements (Table 2). In addition, differ-
ences of the NOTCH1 and FLT3 mutation status between ETP-
ALL and non-ETP T-ALL cases were explored. We found a low
rate of NOTCH1 mutations in the ETP-ALL subgroup (n=10/68,
15%), whereas NOTCH1 mutations were more frequent (40%) in
non-ETP T-ALL patients (P,.001). In contrast, we found a high
rate of FLT3 mutations in ETP-ALL compared to non-ETP T-
ALL patients: 24 of the 25 FLT3 mutations were found in the
ETP-ALL group, displaying a frequency of 35.3%, whereas non-
ETP T-ALL showed a FLT3 mutations frequency of only 1.2%
(P,.001). Ten cases (6.5%) had TKD mutations, of which nine
occurred in the ETP-ALL group (P=.003). ITD mutations were
found in 15 cases, all belonging to the ETP-ALL group (P,.001,
Table 2). In a multivariate analysis, NOTCH1 mutation status, low
expression of BAALC, WT1, ERG, IGFBP7, and TCR rearrange-
ment had no additional prognostic impact in the subgroup of
ETP-ALL.
FLT3 Mutated ETP-ALL
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In addition to the distinct immunophenotype, FLT3mut ETP-
ALL showed specific immunophenotypic and molecular charac-
teristics compared to FLT3wt ETP-ALL. In this study, 83% (20/
24) of FLT3mut ETP-ALL patients were positive for CD117,
compared to only 28% (13/44) of FLT3wt ETP-ALL cases
(P,.001). Furthermore, FLT3mut ETP-ALL had a higher rate of
positivity for CD2 (88% vs. 30%, P,.001) and CD13 (100% vs.
37%, P,.001) compared to FLT3wt ETP-ALL patients. FLT3wt
ETP-ALL was characterized by expression of CD5 (54% vs. 4%,
P,.001) and CD33 (54% vs. 4%, P,.001; Figure S1 in
Supplementary Figures).
A recent study described the immunophenotype of TdT+/
CD7+/CD13+/CD34+/CD117+ as highly specific for the pre-
diction of FLT3 mutations in an unselected cohort of T-ALL [17].
In our ETP-ALL cohort, 75% (18/24) of patients with FLT3
mutations showed this immunophenotype, while only 7% (3/44)
without FLT3 mutations displayed this phenotype. Another FLT3
mutation associated marker profile (sCD3-/CD117+/CD34+/
CD62L+/CD56-/CD2+/CD7+/CD1a-/CD4-/CD5-/CD8-/CD13
+ [36] can be adopted to 71% (17/24) of our FLT3mut ETP-ALL
patients; this profile was highly specific for FLT3 mutations without a
false prediction. Here we established the combination of CD2+/
CD5-/CD13+/CD33-, able to detect 21 of the 24 FLT3mut ETP-
ALL patients, as highly sensitive (88%) and specific (95%) algorithm
(Table 3).
Molecular characteristics of FLT3mut ETP-ALL in contrast
to FLT3wt ETP-ALL
FLT3mut ETP-ALL showed a specific gene expression profile
compared to FLT3wt ETP-ALL. Higher expression levels of WT1
(2.2-fold, P=.003) and lower expression of IGFBP7 (0.11-fold,
P,.001) were characteristic for FLT3mut ETP-ALL. Remarkably,
Figure 1. Kaplan Meier analysis of overall survival in adult ETP-ALL patients receiving chemotherapy only (without alloSCT) or
undergoing alloSCT. P-value was calculated by the Log-Rank test. Abbreviations: alloSCT, allogeneic stem cell transplantation.
doi:10.1371/journal.pone.0053190.g001
Table 2. Mutational events in ETP-ALL compared to non-ETP
T-ALL.
Mutation Status ETP-ALL non-ETP T-ALL P-value
TCR rearrangement monoclonal 28 (41%) 66 (79%) ,.001
n=153 polyclonal 40 (59%) 18 (21%)
NOTCH1 mut 10 (15%) 35 (41%) ,.001
n=151 wt 56 (85%) 50 (59%)
FLT3 total mut 24 (35%) 1 (1%) ,.001
n=153 wt 44 (65%) 84 (99%)
FLT3 ITD mut 15 (22%) 0 (0%) ,.001
wt 53 (78%) 85 (100%)
FLT3 D835 mut 9 (13%) 1 (1%) .003
wt 59 (87%) 84 (99%)
P values were calculated by Pearson’s Chi-square test and Fisher’s exact test,
respectively.
doi:10.1371/journal.pone.0053190.t002
FLT3 Mutated ETP-ALL
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cell transcription factor GATA3 compared to FLT3wt ETP-ALL
(P,.001). All except one FLT3mut ETP-ALL case had GATA3
expression levels below the median. No significant differences were
found for BAALC, ERG, MN1, BCL11B, and MEF2C (Table 3). As
for other lymphoblastic leukemias described [37,38], FLT3 itself is
overexpressed in ETP-ALL. In this subgroup FLT3mut ETP-ALL
showed a higher expression compared to FLT3wt ETP-ALL
samples (P,.01, Figure S2 in Supplementary Figures).
TCR rearrangement analysis demonstrated that FLT3mut
ETP-ALL patients predominantly lacked clonal TCR rearrange-
ments. Only 21% of the FLT3mut ETP-ALL patients in contrast
to 52% of the FLT3wt ETP-ALL patients showed a TCR
rearrangement (P=.01). In addition, none of the FLT3mut ETP-
ALL patients showed a NOTCH1 mutation, while 23% (10/44)
FLT3wt ETP-ALL had NOTCH1 mutations (Table 4).
Clinical characteristics of FLT3 mutated ETP-ALL patients
With respect to clinical characteristics, no differences were
observed between the FLT3mut ETP-ALL and the FLT3wt ETP-
ALL patients regarding sex and age. The response to induction
therapy was similar between both groups (CR: 13/21 vs. 13/24).
Three of the 24 FLT3mut ETP-ALL patients were treated with an
AML protocol, but none of the patients with FLT3wt ETP-ALL
(Supplementary Table S3). The overall survival rate was similar
between FLT3mut ETP-ALL and FLT3wt ETP-ALL patients (3-
year survival: 58% versus 61%, P=0.86; Figure S3 in Supple-
mentary Figures).
Sensitivity of T-ALL cell lines transfected with FLT3
expression constructs to TKI
In order to assess the sensitivity of TKI in a model of T-ALL
with FLT3-ITD mutations, we transfected the T-ALL cell lines
Jurkat, BE13 and MOLT-4 with FLT3-ITD or FLT3-wt
constructs and an empty vector as control. Transfection of FLT3
expression constructed did not alter the surface expression of
myeloid (CD13, CD33) or stem cell (CD34, CD117) markers (data
not shown). Cell lines transfected with FLT3-wt and FLT3-ITD
constructs revealed a growth advantage compared to the empty
vector transfected cells DMSO (first columns in Figure 2A–C).
Treatment with TKI resulted in a selective and significant
inhibition of the proliferation of FLT3-wt or FLT3-ITD trans-
fected cells: Jurkat cells transfected with FLT3-ITD or FLT3-wt
constructs showed a significant decrease in proliferation compared
to empty vector transfected cells when treated with TKIs
(including Sorafenib, PKC412, TKI258; Figure 2A). FLT3-ITD
and FLT3-wt transfected cells were almost equally sensitive to
PKC412 and TKI258, whereas empty vector transfected cells
were relative insensitive. Similar results were observed for FLT3-
ITD transfected MOLT-4 (Figure 2B) and BE13 cells (Figure 2C).
FLT3-wt transfected cells behave different for MOLT-4 and
BE13; MOLT-4 cells were more sensitive to sorafenib and BE13
cells were more resistant to PKC412 and TKI258. No differences
in proliferation were observed with respect to the FLT3 status for
AraC treated cells (Figure 2A–C).
We further examined the TKI mediated apoptosis in Jurkat cells
transfected with FLT3 expressing constructs. All TKIs induced
enhanced apoptosis in cells transfected with FLT3 expressing
constructs compared to empty vector controls (Figure S4 in
Supplementary Figures). Cells treated with Sorafenib revealed a
Table 3. Combinations of antigens as a surrogate marker for FLT3 mutations in ETP-ALL.
FLT3mut
(n=24)
FLT3wt
(n=44) P-value Sensitivity Specificity
CD117 pos 20 13 ,.001 83% 70%
neg 4 31
TdT+/CD7+/CD13+/CD34+/CD117+
1 pos 18 3 ,.001 75% 93%
neg 6 41
CD117/CD34+/CD62L+/CD56/CD7+/CD2+/CD5-/CD13+
# pos 17 0 ,.001 71% 100%
neg 7 44
CD2+/CD5-/CD13+/CD33-
& pos 21 2 ,.001 88% 95%
neg 3 42
Abbreviations:
1combination of markers suggested by Hoehn et al. [17],
#combination of markers suggested by Paietta [36],
&combination of markers suggested in this paper. All combinations were adapted to the subgroup of ETP-ALL.
doi:10.1371/journal.pone.0053190.t003
Table 4. Molecular characteristics of FLT3mut ETP-ALL versus
FLT3wt ETP-ALL patients.
A Expression
FLT3mut
(n=24)
FLT3wt
(n=44) P-value
WT1 median (range) 0.78 (0.2–4.2) 0.36 (0.0–3.4) .003
IGFBP7 median (range) 0.30 (0.02–4.0) 2.52 (0.1–9.9) ,.001
GATA3 median (range) 0.06 (0.0–5.7) 5.82 (0.0–6.7) ,.001
BAALC median (range) 0.44 (0.01–17.7) 0.95 (0.0–27.1) .41
ERG median (range) 0.94 (0.2–18.6) 1.56 (0.0–4.2) .16
MN1 median (range) 6.35 (0.3–16.8) 7.42 (0.0–33.1) .29
BCL11B median (range) 0.20 (0.0–1.4) 0.05 (0.0–1.0) .09
MEF2C median (range) 0.71 (0.02–2.2) 0.46 (0.0–5.1) .22
B Mutation Status
NOTCH1 mut 0 (0%) 10 (23%) .01
wt 24 (100%) 34 (77%)
TCR status monoclonal 5 (21%) 23 (52%) .01
polyclonal 19 (79%) 21(48%)
A: P-values were calculated by Mann-Whitney-U-test.
B: P-values were calculated by Pearson’s Chi-square test and Fisher’s exact test,
respectively.
doi:10.1371/journal.pone.0053190.t004
FLT3 Mutated ETP-ALL
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e53190Figure 2. Effects of tyrosine kinase inhibitors on proliferation in T-ALL cell lines transfected with FLT3 expression constructs (A–C).
Fourty-eight hours (hrs) after transfection, cells were seeded and cultured for additionally 48 hrs with tyrosine kinase inhibitors (PKC412, TKI258, and
Sorafenib) and chemotherapy (AraC). Cell proliferation was measured using the WST-1 proliferation reagent. The mean optical density (OD) values
corresponding to non-treated FLT3-ITD transfected cells were taken as 100%. The results were expressed in percentages of the OD of treated versus
untreated control cells. Two experiments were performed in duplicates. For each drug two different doses were used. All results were expressed as
means 6S.D. A: Jurkat cells. B: MOLT4 cells. C: BE13 cells.
doi:10.1371/journal.pone.0053190.g002
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transfected cells, respectively. Similar results were observed for
PKC412 and TKI258 treated cells, whereas no significant changes
in apoptosis were observed for AraC (Figure S4 in Supplementary
Figures). Finally, we defined the concentration (IC50) of Sorafenib,
PKC412, TKI258 and AraC that induced 50% growth inhibition
of Jurkat cells (Figure 3A–D). The IC50 for Sorafenib was
25.7 mM in FLT3-ITD transfected cells, compared to to 305.5 mM
and 486.5 mM in FLT3-wt, and empty vector transfected cells,
respectively (Figure 3A). The IC50 for PKC412 was 2.8 nM in
FLT3-ITD transfected cells, compared to 7.1 nM and 15.5 nM in
FLT3-wt and empty vector transfected cells, respectively
(Figure 3B). Similar growth inhibitory effects were observed for
TKI258 (Figure 3C). No differences in the IC50 between the
different transfected cells were seen for AraC (Figure 3D).
Discussion
In the past decades the molecular characterization of T-ALL
broadly expanded and unraveled key events that drive malignant
transformation. These genetic alterations may in future lead to the
development and the implementation of targeted therapy.
Coustan Smith et al. first identified ETP-ALL as a high risk
subgroup of pediatric T-ALL characterized by a specific immature
immunophenotype and a distinct gene expression profile [4]. Most
recently, the genetic heterogeneity of pediatric ETP-ALL was
further assessed by whole genome sequencing and next generation
sequencing [6]. While various novel somatic mutations were
identified, no single alteration could be detected pointing to the
heterogeneous genetic background of ETP-ALL, despite the
apparently common clinical and immunophenotype features.
However, features shared with myeloid leukemias were present
as well as mutations in genes of cytokine receptor and RAS
signaling and genes involved in histone-modification were
frequently observed [6]. In this work, we now focused on genes
with already established prognostic and pathogenic value in AML
and/or T-ALL.
We have previously characterized ETP-ALL as a high risk
subgroup of early T-ALL in adults [22]. To further delineate the
molecular pathomechanisms for this distinct T-ALL subgroup
with stem cell like and myeloid features, we examined molecular
alterations and clinical outcome in a large cohort of adult ETP-
ALL patients (n=68).
ETP-ALL is defined by a specific immunophenotype as
described [4]. Recently, an additional score based on the
immunophenotype was suggested to define ETP-ALL [39]. In
our ETP-ALL cohort, 96% (65/68) of patients had a score greater
than 6, which we used as the defining cut-off. In addition to this
distinct phenotype, expression analyses of candidate genes
revealed significant higher expression of stem cell associated genes
and genes with adverse prognostic significance in ETP-ALL versus
non-ETP T-ALL. High expression of BAALC and IGFBP7,
associated with an immature high risk leukemic phenotype in
adult T-ALL and AML [26,40], underscores the immature nature
of ETP-ALL. Similarly, IGFBP7, like MEF2C, were also found to
be significantly upregulated in pediatric ETP-ALL [4]. In
addition, MN1 identified to be associated with ETP-ALL [32],
and WT1, a gene known to be of unfavorable prognosis in AML as
well as in T-ALL in the presence of a mutation [25,41], were also
overexpressed in the cohort of ETP-ALL.
We further observed distinct differences in the mutational
profile: compared to non-ETP T-ALL, ETP-ALL patients showed
less frequent NOTCH1 mutations (15%). On the other hand, a
Figure 3. Growth inhibition of Jurkat cells transfected with FLT3 expression constructs (FLT3-ITD, FLT3-wt, and empty vector) and
treated with Sorafenib, PKC412, TKI258 and AraC. IC50 was determined by WST-1 assay with different concentrations.
doi:10.1371/journal.pone.0053190.g003
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contrasting the mutational profile of non-ETP T-ALL. FLT3
mutations are one of the most frequent genetic alterations in AML
[18], whereas FLT3 is only infrequently mutated in leukemic
lymphoblasts [42]. This underscores to some extent the association
of ETP-ALL with early myeloid differentiation. In pediatric
patients, a similar low rate of NOTCH1 mutations (16%) was seen
in ETP-ALL. FLT3 mutations, although in a lower frequency
(14%), occurred exclusively in ETP-ALL [6]. In addition, we
analyzed the TCR rearrangement status in these ETP-ALL
patients. In normal human T-cell development, TCR rearrange-
ments are rare in prothymocytes, but are commonly found at the
prethymocyte stage [43,44]. The frequent absence of TCR
rearrangement in our cohort confirms the immaturity of ETP-
ALL. Together, these data further indicate that ETP-ALL
represents a distinct leukemic subtype.
Interestingly, within the ETP-ALL subgroup FLT3mut ETP-
ALL define a new molecular stem cell entity as these cases show a
specific immunophenotype and molecular characteristics com-
pared to FLT3wt ETP-ALL. We observed a high expression of
CD2, the myeloid antigen CD13, and CD117 in the FLT3mut
ETP-ALL. CD117, encoded by the c-KIT protooncogene, is highly
expressed at the early stages of hematopoietic development [45],
and in acute leukemia the highest frequency of CD117 expression
is found in AML [46–48]. Expression of CD117 has been
associated with FLT3 mutations in rare cases of T-ALL [15,16].
Here, in this yet largest cohort of FLT3mut T-ALL cases, only four
FLT3mut patients lacked CD117 expression. Recently, combina-
tions of surface markers were suggested as surrogate marker for
FLT3 mutations in T-ALL [17,36]. However, while these
combinations yield a high sensitivity, none could detect all of the
ETP-ALL cases with FLT3mut. In our study, a combination of
CD2+/CD5-/CD13+/CD33- resulted in the highest sensitivity for
the presence of FLT3 mutations in ETP-ALL with a high
specificity. For the routinely performed diagnostic flow cytometry,
these combinations may help to identify ETP-ALL patients that
should be tested for FLT3 mutations.
We further observed that FLT3mut ETP-ALL predominantly
lacked clonal TCR-rearrangements pointing to a leukemic
transformation before the prothymocyte stage of T-cell develop-
ment. The absence of TCR rearrangements had already been
linked to early treatment failure in children with T-ALL [49],
providing an indirect support for the poor prognosis of ETP-ALL.
The early developmental arrest of FLT3mut ETP-ALL is also
emphasized by the low GATA3 expression. In normal T-cell
development, GATA3 plays a definite role in the early T-lineage
specification as it is required for the transformation of the ETP/
DN1 to the DN2a stage [34]. Thus the leukemic transformation in
FLT3mut ETP-ALL lacking GATA3 expression might occur at a
stem cell pluripotent prothymic stage before GATA3 expression is
induced. These data in combination with the absence of activating
NOTCH1 mutations reflect an even more immature nature of the
FLT3mut ETP-ALL within the ETP-ALL subgroup.
ETP-ALL as a subgroup of early T-ALL reflects a high risk
entity with an overall survival of approximately 50% in adults
[22]. Based on the findings of the GMALL study group [50], an
alloSCT should be planned in first complete remission for early T-
ALL patients. Even though the selection for patients undergoing
alloSCT is biased due to various confounding parameters, ETP-
ALL patients receiving an alloSCT showed a remarkable favorable
outcome in our cohort, whereas the outcome for ETP-ALL
patients receiving chemotherapy was relatively poor. The poor
response to lymphoid cell-directed ALL chemotherapy only, as
already reported for pediatric ETP-ALL [4], might be due to the
immature nature and myeloid characteristic of the ETP-ALL.
Thus, to further improve outcome for these high risk patients, in
addition to alloSCT the implementation of targeted therapies
should be considered. Due to the high frequency of FLT3
mutations in ETP-ALL, TKIs already studied in FLT3 mutated
AML [51,52] would be an attractive treatment option. We
assessed the sensitivity of T-ALL cell lines transfected with FLT3-
ITD and FLT3-wt expression constructs and observed that FLT3
transfected T-ALL cells, despite of their enhanced proliferation,
were particular sensitive to TKIs similar to results in AML [31].
Although the transfection of FLT3 expression constructs in T-ALL
cell lines remains an in vitro system, the distinct sensitivity to TKIs
together with the positive experience in AML support the rational
for the clinical use of TKIs in FLT3mut ETP-ALL. In this work,
TKI side effects and the impact of TKI on the FLT3 D835Y
mutation were not evaluated. However, in analogy to AML it
would be expected that the tested TKI are also able to target TKD
mutations. Regarding side effects in the clinical use of TKI, the
experience in AML have shown that chemotherapy backbone in
combination TKIs have to be carefully chosen.
Herein, we describe that ETP-ALL patients represent a distinct
molecular subgroup of adult T-ALL patients with a low frequency
of NOTCH1 mutations and a high rate of FLT3 mutations.
Moreover, we characterize FLT3mut ETP-ALL as a new subgroup
of ETP-ALL with unique immunophenotypical and molecular
features pointing to a stem cell leukemia. To further improve
outcome of this high risk leukemia, targeted therapies with TKIs as
well as the allocation to alloSCT should further explored.
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